1 BTC
=
- USD
Apellis Pharmaceuticals, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Apellis Pharmaceuticals, Inc. Common Stock
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
Market Statistics
Trading Metrics
How to Buy APLS
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy APLS
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesBiogen stock fell 4.97% after reporting Phase 2 results for its Alzheimer's drug diranersen, which missed its primary endpoint but showed cognitive benefits and tau biomarker reductions across all doses. The company plans to advance the therapy to registrational development. Separately, Biogen completed its acquisition of Apellis Pharmaceuticals, adding two commercial drugs worth $689 million in 2025 revenue.
Biogen has successfully completed its acquisition of Apellis Pharmaceuticals for $41 per share plus contingent value rights. The deal adds two commercialized products—EMPAVELI and SYFOVRE—which generated $689 million in net product revenue in 2025. The acquisition is expected to be accretive to Biogen's non-GAAP diluted EPS in 2027 and significantly boost the company's growth outlook, particularly in nephrology.
Biogen shares rose 1.06% to $193.40 despite the FDA extending its review of Leqembi Iqlik by three months to August 24, 2026. The company is also advancing its pipeline through the acquisition of Apellis Pharmaceuticals for $5.6 billion and benefiting from FDA approval of a new high-dose regimen for Spinraza. The stock has gained 63.29% over the past year with positive technical indicators.
The complement inhibitors market is projected to experience strong growth through 2036, driven by rising prevalence of complement-mediated diseases, increased R&D efforts, and approval of new therapeutic agents. The US represents the largest market, with IgAN showing approximately 135,000 diagnosed prevalent cases. Key emerging therapies from major pharmaceutical companies are expected to expand treatment options across multiple indications including PNH, aHUS, CIDP, and IgAN.
Biogen has entered into an agreement with Alloy Therapeutics to accelerate the development of antisense therapies for multiple undisclosed indications. Alloy's AntiClastic ASO platform aims to improve the effectiveness of antisense therapeutics by targeting disease pathways at the RNA level. This partnership follows Alloy's January 2025 collaboration with Sanofi and Biogen's recent acquisition of Apellis Pharmaceuticals for $5.6 billion.